Cochrane · systematic review · CD013029
Photobiomodulation for non‐exudative age‐related macular degeneration
Henein, C, Steel, DHW · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
4
No studies
3
Included studies
NR
No studies 3 · 42.9%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 57.1%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Photobiomodulation treatment compared to sham or no treatment for non‐exudative age‐related macular degeneration
Population: people with non‐exudative AMD (AREDS 2 to 4)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Best‐corrected visual acuity at 12 months [logMAR] Measured on the logMAR scale, range ‐1.3 to 1.0. Lower scores represent better vision. Photobiomodulation treatment vs sham or no treatment | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Contrast sensitivity at Level E [18 cycles/degree] at 12 months Higher scores represent better contrast sensitivity. Photobiomodulation treatment vs sham or no treatment | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Near vision Photobiomodulation treatment vs sham or no treatment | no estimate extracted | NR | No studies |
Low luminance deficit score Photobiomodulation treatment vs sham or no treatment | no estimate extracted | NR | No studies |
Reading speed Photobiomodulation treatment vs sham or no treatment | no estimate extracted | NR | No studies |
Self‐reported visual function at 12 months Photobiomodulation treatment vs sham or no treatment | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Adverse events: AMD progression at 12 months Defined as increased drusen volume or onset of advanced AMD. Conversion to exudative AMD at 12 months Assessed by clinical examination and retinal optical coherence tomography. Photobiomodulation treatment vs sham or no treatment | RR 0.79 [0.41, 1.53] | NR | Low Downgraded: risk of bias, imprecision |